Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: BLCO )

19.54 -0.91 (-4.45%)
Official Closing Price Updated: 7:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BLCO

< Previous 1 2 3 4 5 6 Next >
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
From Bausch + Lomb Corporation
Via Business Wire
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
From Bausch + Lomb Corporation
Via Business Wire
7 Analysts Have This to Say About Bausch & Lomb
Via Benzinga
What 7 Analyst Ratings Have To Say About Bausch & Lomb
Via Benzinga
Expert Ratings for Bausch & Lomb
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Acquires AcuFocus, Inc.
From Bausch + Lomb Corporation
Via Business Wire
What 4 Analyst Ratings Have To Say About Bausch & Lomb
Analysts have provided the following ratings for Bausch & Lomb (NYSE:BLCO) within the last quarter: 
Via Benzinga
What 4 Analyst Ratings Have To Say About Bausch & Lomb
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Bausch & Lomb
Within the last quarter, Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings: 
Via Benzinga
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Expert Ratings for Bausch & Lomb
  Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
'Well-Established' Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst
Via Benzinga
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
From Bausch + Lomb Corporation
Via Business Wire
Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13
Benzinga Sam Bankman-Fried Arrested In The Bahamas 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits
More than 50 funds that own Bausch Health Companies Inc (NYSE: BHC) investors are reportedly seeking to block the eye-care business spin-off, Bausch + Lomb Corp (NYSE: BLCO). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
Upgrades 
Via Benzinga
From Corporate Raider To Activist Investor: Here Are Three High-Yielding Stocks Carl Icahn Favors
Formerly known as a "corporate raider," Carl Icahn is the founder and controlling shareholder of Icahn Enterprises, which is a large holding company with well diversified positions. 
Via Benzinga
BHC Stock Continues to Fall as Bausch Health Responds to Court Decision
Although Bausch Health promises to fight back against an unfavorable patent protection ruling, BHC stock is still hurting. 
Via InvestorPlace
Bausch Health (BHC) Stock Plunges 50% on Patent News
With Bausch Health losing a critical patent battle enabling its key drug to suffer generic competition, BHC stock veritably crumbled. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Meta, Charter Communications, Southwest Airlines And Some Other Big Stocks Moving Lower On Thursday
Bausch Health Companies Inc. (NYSE: BHC) shares fell 50.3% to $4.3166 following reports of an order on a patent litigation over Xifaxan. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.